Definium Therapeutics (NASDAQ:DFTX) Shares Gap Up After Analyst Upgrade

Posted by Francis Steltz on Aug 14th, 2026

Definium Therapeutics, Inc. (NASDAQ:DFTX – Get Free Report) shares gapped up before the market opened on Wednesday after JonesTrading raised their price target on the stock from $74.00 to $90.00. The stock had previously closed at $40.91, but opened at $47.51. JonesTrading currently has a buy rating on the stock. Definium Therapeutics shares last traded at $42.85, with a volume of 2,741,718 shares traded.

A number of other brokerages have also issued reports on DFTX. Citigroup restated a “buy” rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Needham & Company LLC upped their price target on shares of Definium Therapeutics from $50.00 to $66.00 and gave the company a “buy” rating in a research report on Wednesday. Canaccord Genuity Group set a $64.00 price target on shares of Definium Therapeutics and gave the stock a “buy” rating in a research note on Thursday. Wall Street Zen lowered shares of Definium Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Finally, Robert W. Baird upped their target price on shares of Definium Therapeutics from $57.00 to $75.00 and gave the company an “outperform” rating in a report on Thursday. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Definium Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $62.69.

Check Out Our Latest Stock Report on Definium Therapeutics

Insider Activity

In other news, insider Mark Sullivan sold 13,008 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $585,750.24. Following the completion of the sale, the insider owned 320,571 shares in the company, valued at approximately $14,435,312.13. This trade represents a 3.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Matthew T. Wiley sold 2,867 shares of Definium Therapeutics stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $129,101.01. Following the completion of the sale, the insider directly owned 174,633 shares in the company, valued at approximately $7,863,723.99. The trade was a 1.62% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 48,096 shares of company stock valued at $2,165,763. 2.40% of the stock is owned by corporate insiders.

Key Headlines Impacting Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

Positive Sentiment: DT120 met its Phase 3 GAD objectives. Definium reported positive topline results from the Voyage study, with DT120 ODT producing a 5.4-point improvement on the Hamilton Anxiety Rating Scale versus placebo. The late-stage result strengthens the potential for DT120 to become a commercially important anxiety treatment. Definium Therapeutics Hits Phase 3 GAD Goals for DT120 ODT
Positive Sentiment: Analysts raised their valuations following the trial update. JonesTrading increased its price target to $90 and maintained a “buy” rating. RBC raised its target to $66 with an “outperform” rating, while Wells Fargo lifted its target to $72 and kept an “overweight” rating. Baird raised its target to $75 and Needham increased its target to $66; all cited the improving outlook for DT120. RBC Comments on Definium Therapeutics DT120 Data
Positive Sentiment: Investor confidence in future development has improved. RBC said the DT120 data increases confidence in subsequent trials and supports the company’s plans across two potential indications. The results follow another positive Phase 3 study, giving investors additional evidence that the program may be advancing toward regulatory submission. Definium Reports Positive Late-Stage Anxiety Study
Neutral Sentiment: The stock’s strong rally has increased expectations for DT120 and may lead to heightened volatility as investors await additional trial details, regulatory steps and the company’s planned September catalyst.
Negative Sentiment: Definium remains loss-making, and HC Wainwright reduced several EPS forecasts. The firm lowered its FY2026 estimate to a loss of $3.05 per share from $2.10 and cut FY2027, FY2028, FY2029 and FY2030 projections. These revisions highlight continued development costs and the risk that profitability remains several years away.

Hedge Funds Weigh In On Definium Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. raised its stake in shares of Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after buying an additional 2,003 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Definium Therapeutics by 56.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock valued at $55,000 after buying an additional 3,020 shares during the period. Caxton Associates LLP purchased a new stake in shares of Definium Therapeutics in the third quarter valued at approximately $126,000. Mercer Global Advisors Inc. ADV boosted its stake in shares of Definium Therapeutics by 10.5% in the third quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock valued at $259,000 after buying an additional 2,079 shares in the last quarter. Finally, Scientech Research LLC acquired a new position in Definium Therapeutics during the third quarter worth $286,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

Definium Therapeutics Price Performance

The company has a 50-day simple moving average of $39.45 and a 200-day simple moving average of $26.71. The stock has a market cap of $4.38 billion, a PE ratio of -12.80 and a beta of 2.23. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.95 and a quick ratio of 6.95.

Definium Therapeutics (NASDAQ:DFTX – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.89). Sell-side analysts anticipate that Definium Therapeutics, Inc. will post -2.81 EPS for the current fiscal year.

Definium Therapeutics Company Profile

(Get Free Report)

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.